Clinical studies confirmed an antitumor effect of KO-539 and VTP50469/SNDX-5613 against MLLr and NPM1m MLL and B-ALL, which had previously been observed in pre-clinical experiments [11,12]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.